Despite recent breakthroughs in targeted therapies (such as KRAS G12C inhibitors) and immunotherapies (such as PD-1/PD-L1 inhibitors) in some solid tumors, pancreatic cancer remains a “therapeutic desert” due to its highly fibrotic tumor microenvironment (TME) and complex cellular interaction networks (2). This evidence concerns the gene CD274 and neoplasm.